Abstract:Chagas disease (CD), a neglected tropical disease, is caused by infection by the protozoan Trypanosoma cruzi . One-third of CD patients develop cardiac disease (CARD), an inflammatory and fibrotic process that may progress to heart failure associated with reduced left ventricular ejection fraction (LVEF). The determinants of CD progression are still uncertain. In non-infectious conditions, the angiotensin-converting enzyme (ACE) functional insertion (I)/deletion (D) and type 1 angiotensin II receptor (AT 1 R) +1166A>C gene polymorphisms have been linked to clinical outcomes. In a Brazilian cohort of 402 patients with positive serology for CD, in a case-control study we used PCR for genotyping the ACE rs4646994 I/D and AGTR1 rs5182C>T, rs275653 -119C>T, rs2131127A>G and rs5186 +1166A>C polymorphisms to evaluate association with CARD and progression to heart failure. Patients were classified as non-CARD (stage A; 109), and mild (stage B1; 161) or severe (stage C; 132) CARD. The groups were compared using unconditional logistic regression analysis and adjusted for non-genetic covariates (age, gender, and trypanocidal treatment). ACE II genotype appeared less frequent in C patients (15% in C vs 20% in B1 and 27% in A). After covariate adjustments, the ACE D allele showed a borderline association with susceptibility to severe CARD (C vs A: OR = 1.9; P = 0.08). AGTR1 +1166AC genotype showed a borderline association with protection against the progression and severity of CARD (C vs A: OR = 0.6; P = 0.09; C vs B1: OR = 0.6; P = 0.07; C vs A + B1: OR = 0.6; P = 0.05). However, adjustments for multiple comparisons showed no association of ACE I/D and AGTR1 polymorphisms with susceptibility and severity of CARD. The rs275653/rs2131127/rs5186/rs5182 T/A/C/T haplotype was protective against progression to the severe form of CARD (C vs B1: OR = 0.3; P = 0.03). Moreover, patients with ACE II and AGTR1 rs5186 +1166AC genotypes presented higher LVEF%. In C patients, TNF serum levels were higher in ACE D carriers than in II genotype. Although limited in number, a cross-sectional observation suggests that C-stage patients treated with benznidazole years prior to administration of ACE inhibitors/AT 1 R antagonists show reduced TNF serum levels and improved LVEF%. Therefore, variants of ACE and AGTR1 genes may influence the outcome of Chagas' heart disease and should be explored in precision medicine. Further, pharmacotherapies may improve immunological abnormality and clinical outcome in CD patients. Altogether, these data support prospective studies of this cohort and replication in other cohorts. It is estimated that 6–7 million individuals worldwide are infected with Trypanosoma cruzi , the etiologic agent of Chagas disease (CD), a neglected illness that impacts public health. Chronic cardiopathy is the most severe manifestation of CD, an inflammatory and fibrotic process that can progress to heart failure with reduced left ventricular ejection fraction (LVEF). Host genetics may be a determining factor in the progression of CD. In a group of chronic CD patients, we evaluated genetic polymorphisms of members of the renin-angiotensin system ( ACE I/D; AGTR1 variants), essential in regulating blood pressure and cardiovascular events. ACE D allele carriers and AGTR1 rs5186 +1166AA genotype present worse LVEF. Thus, variants of ACE and AT 1 R genes may be involved in the outcome of Chagas' heart disease. Although studying a low number of patients with severe cardiopathy, our data suggest that etiological treatment years before therapy with cardioprotectors (ACE inhibitors/AT 1 R blockers) reduced serum levels of TNF, an inflammatory cytokine important in cardiac pathology, and improved LVEF. This paves the way for ACE and AGTR1 genotyping, and adoption of therapeutic regimens may be explored as strategies for precision medicine in CD patients. Replicating of these findings in other cohorts is essential.

TNF blockade aggravates experimental chronic Chagas disease cardiomyopathy

Co-Exposure of Cardiomyocytes to IFN-γ and TNF-α Induces Mitochondrial Dysfunction and Nitro-Oxidative Stress: Implications for the Pathogenesis of Chronic Chagas Disease Cardiomyopathy

TNF blockers alone and associated with Benznidazole impact in vitro cytokine dynamics in chronic Chagas disease

Tolerogenic Dendritic Cells Reduce Cardiac Inflammation and Fibrosis in Chronic Chagas Disease

The effects of inflammation on connexin 43 in chronic Chagas disease cardiomyopathy

PPARγ ligand treatment inhibits cardiac inflammatory mediators induced by infection with different lethality strains of Trypanosoma cruzi

Preclinical evaluation of combined therapy with amiodarone and low-dose benznidazole in a mouse model of chronic Trypanosoma cruzi infection

Inflammation and mitochondria in the pathogenesis of chronic Chagas disease cardiomyopathy

Association between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease

Impairment of Multiple Mitochondrial Energy Metabolism Pathways in the Heart of Chagas Disease Cardiomyopathy Patients

MyD88 activation in cardiomyocytes contributes to the heart immune response to acute Trypanosoma cruzi infection with no effect on local parasite control

Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease

Cardiac Abnormalities in a Predictive Mouse Model of Chagas Disease

Differential Expression of Matrix Metalloproteinases 2, 9 and Cytokines by Neutrophils and Monocytes in the Clinical Forms of Chagas Disease

Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy

Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease

Signatures of CD4+ T and B cells are associated with distinct stages of chronic chagasic cardiomyopathy

Adipose Tissue-Derived Mesenchymal Stromal Cells Protect Mice Infected with Trypanosoma cruzi from Cardiac Damage through Modulation of Anti-parasite Immunity

Immunoregulatory mechanisms in Chagas disease: modulation of apoptosis in T-cell mediated immune responses

Influence of angiotensin II type 1 receptors and angiotensin-converting enzyme I/D gene polymorphisms on the progression of Chagas' heart disease in a Brazilian cohort: Impact of therapy on clinical outcomes

Exercise Training Reduces Inflammation and Fibrosis and Preserves Myocardial Function and Perfusion in a Model of Chronic Chagas Cardiomyopathy